Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 8/2016

01-08-2016 | Autoimmunity (TK Tarrant, Section Editor)

Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity

Authors: Luanna Yang, Eveline Y. Wu, Teresa K. Tarrant

Published in: Current Allergy and Asthma Reports | Issue 8/2016

Login to get access

Abstract

Immune gamma globulin (IgG) has a long history in the treatment of both primary immune deficiency and autoimmune disorders. Disease indications continue to expand and new-generation products increase the versatility of delivery. This review encompasses a historical perspective as well as current and future implications of human immune globulin for the treatment of immune-mediated illness.
Literature
1.
2.
Berger M. A history of immue globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2(5):368–78.CrossRefPubMed
3.
Bruton OC. Agammaglobulinemia (congenital absence of gamma globulin); report of a case. Med Ann Dist Columbia. 1953;22(12):648–50. passim.PubMed
4.••
Wood P. Immunotherapy for primary immunodeficiency diseases. Med Clin N Am. 2012;96(3):433–54, ix. doi:10.​1016/​j.​mcna.​2012.​04.​010. This is a comprehensive review for immune globulin in the treatment of PIDD.
5.
6.
7.
Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43:1460–80.CrossRefPubMed
8.
9.
Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265–73. doi:10.​1007/​s10875-006-9021-7.CrossRefPubMed
10.
11.
Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367–75.CrossRefPubMed
12.
Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005;25(11 Pt 2):78S–84S.CrossRefPubMed
13.
14.
Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol. 2000;19(2):183–204.CrossRefPubMed
15.
16.
17.
18.
McCusker C, Warrington R. Primary immunodeficiency. Allergy, Asthma Clin Immunol. 2011;7 Suppl 1:S11.CrossRef
19.
20.•
Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol. 2013;33 Suppl 2:S90–4. doi:10.​1007/​s10875-012-9838-1. This is a review for the treatment of PIDD with immune globulin.
21.••
Albin S, Cunningham-Rundles C. Update on the use of immunoglobulin for the treatment of immunodeficiency disorders. Immunotherapy. 2014;6(10):1113–26. This is a comprehensive review for immune globulin in the treatment of PIDD.
22.
Sweinberg SK, Wodell RA, Greene JM, Conley ME. Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. J Allergy Clin Immunol. 1991;88(1):96–104.CrossRefPubMed
23.
Liese JG, Wintergerst U, Tympner KD, Belohradsky BH. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child. 1992;146(3):335–9.PubMed
24.
25.
Quartier P, Debré M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134(5):589.CrossRefPubMed
26.
27.
Aghamohammadi A, Moin M, Farhoudi A, Rezaei N, Pourpak Z, Movahedi M, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol. 2004;40(2):113–8. doi:10.​1016/​s0928-8244(03)00304-3.CrossRefPubMed
28.
29.
Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies EG, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood. 2011;117(11):3243–6. doi:10.​1182/​blood-2010-08-.CrossRefPubMed
30.
Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013;33(7):1156–64. doi:10.​1007/​s10875-013-9917-y.CrossRefPubMedPubMedCentral
31.
Buckley RH. Advances in the understanding and treatment of human severe combined immunodeficiency. Immunol Res. 2000;200(2–3):237–51.CrossRef
32.•
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–53. doi:10.​1016/​j.​jaci.​2006.​01.​015. This is a position statement by members of the Primary Immune Deficiency Committee of the American Academy of Allergy, Asthma, and Immunology on the therapeutic indications of IgG in human disease.
33.
Pruzanski W, Sussman G, Dorian W, Van T, Ibanez D, Redelmeier D. Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation. 1996;20(4):353–9.CrossRefPubMed
34.
Pettit S, Bourne H, Spickett GP. Survey of infection in patients receiving antibody replacement treatment for immune deficiency. J Clin Pathol. 2002;55(8):577–80.CrossRefPubMedPubMedCentral
35.
36.
Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26(2):177–85. doi:10.​1007/​s10875-006-9002-x.CrossRefPubMed
37.
38.
39.
Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–31.CrossRefPubMed
40.
41.
Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune γ-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol. 2001;21:193–9.CrossRefPubMed
42.
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. Am Heart Assoc Circ. 2004;110(17):2747–71. doi:10.​1161/​01.​CIR.​0000145143.​19711.​78.
43.
Zhang G, Lopez P, Li CY, Mehta NR, Griffin JW, Schnaar RL, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain. 2004;127(5):1085–100. doi:10.​1093/​brain/​awh127Brain.CrossRefPubMed
44.
45.
46.
47.
48.
49.
Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–7. doi:10.​1007/​s00431-006-0223-z.CrossRefPubMed
50.
51.
52.
53.
54.
55.
Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;4:CD004000.PubMed
56.
57.
Bromberg ME. Immune thrombocytopenic purpura—the changing therapeutic landscape. N Engl J Med. 2006;355(16):1643–5.CrossRefPubMed
58.
59.
60.
Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160:1630–8.CrossRefPubMed
61.
British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and managemet of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–96.CrossRef
62.
63.
Godeau B, Chevret S, Varet B, Lefrere F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359(9300):23–9. doi:10.​1016/​s0140-6736(02)07275-6.CrossRefPubMed
64.
Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(9):831–6.CrossRefPubMed
65.
Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401–7. doi:10.​1182/​blood-2005-.CrossRefPubMed
66.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86. doi:10.​1182/​blood-2009-06-.CrossRefPubMed
67.
Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1g/kg b.w. Br J Haematol. 1999;107(4):716–9.CrossRefPubMed
68.
69.
Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and campylobacter jejuni infections in Japan. Ann Neurol. 2000;48(4):624–31.CrossRefPubMed
70.
71.
72.
The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology. 1985;35(8):1096–104.CrossRef
73.
van der Meché FGA, Schmitz PIM. Randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326(17):1123–29.CrossRefPubMed
74.
Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996;46(1):100–3.CrossRefPubMed
75.
Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349(9047):225–30.CrossRef
76.
Diener HC, Haupt WF, Kloss TM, Rosenow F. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol. 2001;46(2):107–9.CrossRefPubMed
77.
Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunogobulin in the treatment of neuromuscular disorders. Neurology. 2012;78:1009–15.CrossRefPubMed
78.
Hughes R, Swan A, van Doorn P. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;9:CD002063.PubMed
79.
Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet. 1993;341(8845):586–90.
80.
van Koningsveld R, Schmitz PIM, van der Meché FGA, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004;363(9404):192–6. doi:10.​1016/​s0140-6736(03)15324-x.CrossRefPubMed
81.
82.
Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50(2):195–201.CrossRefPubMed
83.
Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56(4):445–9.CrossRefPubMed
84.
Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11:493–502. doi:10.​1016/​S1474-.CrossRefPubMed
85.
86.
Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–44. doi:10.​1016/​s1474-4422(07)70329-0.CrossRefPubMed
87.
Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;12:CD001797.PubMed
88.
Roper AH. Current treatments for CIDP. Neurology. 2003;60 Suppl 3:S16–22.CrossRef
89.
90.
Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17(4):241–51.
91.
92.
Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21(2):105–16.CrossRefPubMed
93.
Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133(2):247–51.CrossRefPubMedPubMedCentral
94.
CDC. Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. JAMA. 1994;272:424–5.CrossRef
95.
Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365–9.CrossRefPubMed
96.
Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94–100.CrossRefPubMed
97.
Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous Ig GSG. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265–73. doi:10.​1007/​s10875-006-9021-7.CrossRefPubMed
98.
Borte M, Quinti I, Soresina A, Fernandez-Cruz E, Ritchie B, Schmidt DS, et al. Efficacy and safety of subcutaneous vivaglobin (R) replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol. 2011;31(6):952–61. doi:10.​1007/​s10875-011-9588-5.CrossRefPubMed
99.
Bezrodnik L, Gomez Raccio A, Belardinelli G, Regairaz L, Diaz Ballve D, Seminario G, et al. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina. J Clin Immunol. 2013;33(7):1216–22. doi:10.​1007/​s10875-013-9916-z.CrossRefPubMed
100.
101.
Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharm Des. 2011;17:3166–75.CrossRefPubMed
102.
103.
Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6(5):553–67.CrossRefPubMed
Metadata
Title
Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity
Authors
Luanna Yang
Eveline Y. Wu
Teresa K. Tarrant
Publication date
01-08-2016
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 8/2016
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-016-0632-7

Other articles of this Issue 8/2016

Current Allergy and Asthma Reports 8/2016 Go to the issue

Asthma (WJ Calhoun and V Ortega, Section Editors)

Airway Microbiota and the Implications of Dysbiosis in Asthma

Asthma (WJ Calhoun and V Ortega, Section Editors)

What Ancestry Can Tell Us About the Genetic Origins of Inter-Ethnic Differences in Asthma Expression

Rhinitis (JJ Oppenheimer and J Corren, Section Editors)

Capsaicin for Rhinitis

Rhinitis (JJ Oppenheimer and J Corren, Section Editors)

Botulinum Toxin for Rhinitis

Otitis (D Skoner, Section Editor)

Eosinophil ETosis and DNA Traps: a New Look at Eosinophilic Inflammation

Immunologic/Diagnostic Tests in Allergy (M Chapman and A Pomés, Section Editors)

Pros and Cons of Clinical Basophil Testing (BAT)